1-bromo-4-methoxy-3-(4-ethylbenzyl)benzene | 333361-59-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-bromo-4-methoxy-3-(4-ethylbenzyl)benzene
• 英文别名: 5-bromo-2-methoxy-4'-ethyldiphenylmethane；4-bromo-2-(4-ethylbenzyl)-1-methoxybenzene；4-Bromo-2-[(4-ethylphenyl)methyl]-1-methoxybenzene
• CAS: 333361-59-4
• 化学式: C₁₆H₁₇BrO
• 分子量: 305.214
• InChiKey: FLSVRVOJAIFPOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-bromo-4-methoxy-3-(4-ethylbenzyl)benzene 在 三乙基硅烷 、 正丁基锂 、 三氟乙酸 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 1.67h， 生成 ((((1S,2R,3R,4R,6R)-4-[(benzyloxy)methyl]-6-[3-(4-ethylbenzyl)-4-methoxyphenyl]cyclohexane-1,2,3-triyl)tris(oxy))tris(methylene))tribenzene
  参考文献：
  名称：

  EP1783110

  摘要：

  公开号：
• 作为产物：
  描述：

  5-溴-2-甲氧基苯甲醛 在 三乙基硅烷 、 三氟化硼乙醚 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.17h， 生成 1-bromo-4-methoxy-3-(4-ethylbenzyl)benzene
  参考文献：
  名称：

  C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  摘要：

  C-Aryl 5a-carba-beta-D-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2. Modifications to the substituents on the two benzene rings resulted in enhanced hSGLT2 inhibition activity and extremely high hSGLT2 selectivity versus SGLT1. Using the created superimposed model, the reason for the high hSGLT2 selectivity was speculated to be that additional substituents occupied a new space, in a different way than known inhibitors. Among the tested compounds, the ethoxy compound 5h with high hSGLT2 selectivity exhibited more potent and longer hypoglycemic action in db/db mice than our O-carbasugar compound (1) and sergliflozin (2), which could be explained by its improved PK profiles relative to those of the two compounds. These results indicated that 5h might be a promising drug candidate for the treatment of type 2 diabetes. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.053

文献信息

• C-aryl glucoside SGLT2 inhibitors and method
  申请人：——

  公开号：US20030114390A1

  公开（公告）日：2003-06-19

  A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula 1 alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).

  提供了一种用于治疗糖尿病及相关疾病的方法，使用化合物formula1的SGLT2抑制剂量，可以单独使用，也可以与一个或多个其他抗糖尿病药物或其他治疗药物组合使用。
• [EN] C-ARYL GLUCOSIDE SGLT2 INHIBITORS<br/>[FR] INHIBITEURS DE SGLT2 A BASE DE GLUCOSIDE C-ARYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2001027128A1

  公开（公告）日：2001-04-19

  SGLT2 inhibiting compounds are provided having formula (I) where R?1, R2, and R2a¿ are independently hydrogen, OH, OR5, lower alkyl, CF¿3?, OCHF2, OCF3, SR?5i¿ or halogen, or two of R?1, R2 and R2a¿ together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle; R?3 and R4¿ are independently hydrogen, OH, OR5a, OAryl, OCH¿2?Aryl, lower alkyl, cycloalkyl, CF3, -OCHF2, -OCF3, halogen, -CN, -CO2R?5b, -CO¿2H, -COR6b, -CH(OH)R6c, -CH(OR?5h)R6d, -CONR6R6a¿, -NHCOR5c, -NHSO¿2R?5d, -NHSO¿2?Aryl, Aryl, -SR?5e, -SOR5f, SO¿2R5g, SO2Aryl, or a five, six or seven membered heterocycle, or R?3 and R4¿ together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle; R?5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h, and R5I¿ are independently lower alkyl; R?6, R6a, R6b, R6c and R6d¿ are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R?6 and R6a¿ together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle; A is O, S, NH, or (CH¿2?)n where n is 0 - 3. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

  提供具有公式（I）的SGLT2抑制化合物，其中R?1，R2和R2a¿独立地是氢，OH，OR5，低碳基，CF¿3？，OCHF2，OCF3，SR?5i¿或卤素，或者R?1，R2和R2a¿中的两个与它们附着的碳可以形成一个嵌环的五元，六元或七元碳环或杂环；R?3和R4¿独立地是氢，OH，OR5a，OAryl，OCH¿2？Aryl，低碳基，环烷基，CF3，-OCHF2，-OCF3，卤素，-CN，-CO2R?5b，-CO¿2H，-COR6b，-CH（OH）R6c，-CH（OR?5h）R6d，-CONR6R6a¿，-NHCOR5c，-NHSO¿2R?5d，-NHSO¿2？Aryl，芳基，-SR?5e，-SOR5f，SO¿2R5g，SO2Aryl或五元，六元或七元杂环，或R?3和R4¿与它们附着的碳形成一个嵌环的五元，六元或七元碳环或杂环；R?5，R5a，R5b，R5c，R5d，R5e，R5f，R5g，R5h和R5I¿独立地是低碳基；R?6，R6a，R6b，R6c和R6d¿独立地是氢，烷基，芳基，烷基芳基或环烷基，或者R?6和R6a¿与它们附着的氮一起形成一个嵌环的五元，六元或七元杂环；A是O，S，NH或（CH¿2？）n，其中n为0-3。还提供了一种使用上述化合物的SGLT2抑制量单独或与另一种抗糖尿病药物或其他治疗药物组合治疗糖尿病和相关疾病的方法。
• Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes
  申请人：Matsuoka Hiroharu

  公开号：US20080318874A1

  公开（公告）日：2008-12-25

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH 2 —, or —NH—; n is an integer selected between 0 and 1; R 6 and R 7 each independently is hydrogen or C 1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q 1 to Q 5 ; Ar 1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar 2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，如持久的药物活性、代谢稳定性和安全性；以及用于预防或治疗与高血糖相关的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是-O-、-CH2-或-NH-；n是在0和1之间选择的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选择的整数；Q在以下式Q1至Q5之间选择；Ar1是可选的取代芳基或可选的取代杂环芳基，但杂环芳基可以与芳香环或芳香杂环结合形成融合环；Ar2是可选的取代芳基或可选的取代杂环芳基），该化合物的前药物或任一药物学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• 一类烷氧苯基丙二醇衍生物和用途
  申请人：佛山市赛维斯医药科技有限公司

  公开号：CN104478674B

  公开（公告）日：2016-03-09

  本发明涉及与糖尿病相关的药物领域。具体而言，本发明涉及一类烷氧苯基丙二醇结构的II型钠依赖性葡萄糖转运子(SGLT2)抑制剂、其制备方法、以及在制备治疗糖尿病药物中的应用。，其中，R1选自C1-C3的烷基；R2选自C1-C3的烷基。
• NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1783110A1

  公开（公告）日：2007-05-09

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优越性能，如持久的药物活性、代谢稳定性和安全性；以及一种药物组合物，用于预防或治疗由高血糖引起的疾病，如糖尿病，如胰岛素依赖型糖尿病（1型糖尿病）或非胰岛素依赖型糖尿病（2型糖尿病）、糖尿病并发症和肥胖症。衍生物是由式（I）代表的化合物： (其中 A 是-O-、-CH2-或-NH-；n 是选自 0 和 1 之间的整数；R6 和 R7 各自独立地是氢或 C1-6 烷基；m 是选自 1-3 之间的整数；Q 是选自下式 Q1 至 Q5 之间的整数； Ar1是任选取代的芳基或任选取代的杂芳基，条件是杂芳基可以键合到芳香族碳环或芳香族杂环上以形成融合环；以及Ar2是任选取代的芳基或任选取代的杂芳基）、该化合物的原药或二者的药学上可接受的盐。还提供了含有该化合物的药物、药物组合物或类似物。